Items where Author is "Pohl, C."

2020

Wuelser, G. G. and Chesney, M. and Mayer, H. and Niggli, U. and Pohl, C. and Sahakian, M. and Stauffacher, M. and Zinsstag, J. and Edwards, P.. (2020) Priority themes for swiss sustainability research. Swiss Academies Reports, 15. pp. 1-56.

2011

Acaster, S. and Swinburn, P. and Wang, C. and Stemper, B. and Beckmann, K. and Knappertz, V. and Pohl, C. and Sandbrink, R. and Gondek, K. and Edan, G. and Kappos, L. and Freedman, M. and Hartung, H.-P. and Arnason, B. and Comi, G. and Filippi, M. and Jeffery, D. and O'Connor, P. and Cook, S. and Lloyd, A. J.. (2011) Can the functional assessment of multiple sclerosis adapt to changing needs? : a psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 17 (12). pp. 1504-1513.

Waschbisch, A. and Sandbrink, R. and Hartung, H.-P. and Kappos, L. and Schwab, S. and Pohl, C. and Wiendl, H.. (2011) Evaluation of soluble HLA-G as a biomarker for multiple sclerosis. Neurology, Vol. 77, H. 6. pp. 596-598.

Filippi, M. and Rocca, M. A. and Camesasca, F. and Cook, S. and O'Connor, P. and Arnason, B. G. W. and Kappos, L. and Goodin, D. and Jeffery, D. and Hartung, H.-P. and Comi, G. and Wolinsky, J. S. and Bogumil, T. and Pohl, C. and Beckmann, K. and Sandbrink, R. and Croze, E. and Brown, C. and Desimone, T. M. and Arnold, D. L. and Cutter, G. and Knappertz, V.. (2011) Interferon β-1b and glatiramer acetate effects on permanent black hole evolution. Neurology, Vol. 76, H. 14. pp. 1222-1228.

Hartung, H.-P. and Freedman, M. S. and Polman, C. H. and Edan, G. and Kappos, L. and Miller, D. H. and Montalbán, X. and Barkhof, F. and Petkau, J. and White, R. and Sahajpal, V. and Knappertz, V. and Beckmann, K. and Lanius, V. and Sandbrink, R. and Pohl, C. and Benefit Study Group, . (2011) Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology, Vol. 77, H. 9. pp. 835-843.

2010

van den Elskamp, I. J. and Boden, B. and Dattola, V. and Knol, D. L. and Filippi, M. and Kappos, L. and Fazekas, F. and Wagner, K. and Pohl, C. and Sandbrink, R. and Polman, C. H. and Uitdehaag, B. M. J. and Barkhof, F.. (2010) Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology, Vol. 52, H. 10. pp. 875-881.

van den Elskamp, I. J. and Knol, D. L. and Vrenken, H. and Karas, G. and Meijerman, A. and Filippi, M. and Kappos, L. and Fazekas, F. and Wagner, K. and Pohl, C. and Sandbrink, R. and Polman, C. H. and Uitdehaag, B. M. J. and Barkhof, F.. (2010) Lesional magnetization transfer ratio : a feasible outcome for remyelinating treatment trials in multiple sclerosis. Multiple Sclerosis Journal, 16 (6). pp. 660-669.

2008

Polman, C. and Kappos, L. and Freedman, M. S. and Edan, G. and Hartung, H. P. and Miller, D. H. and Montalbán, X. and Barkhof, F. and Selmaj, K. and Uitdehaag, B. M. and Dahms, S. and Bauer, L. and Pohl, C. and Sandbrink, R. and Benefit, investigators. (2008) Subgroups of the BENEFIT study : risk of developing MS and treatment effect of interferon beta-1b. Journal of neurology, Vol. 255, H. 4. pp. 480-487.